PCM
CTMX icon

Piermont Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Piermont Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$229K – 133
2018
Q2 		$229K Sell
10,000
-1,820
-15% -$46.5K 0.07% 224
2018
Q1 		$336K Sell
11,820
-1,850
-14% -$52.8K 0.11% 213
2017
Q4 		$289K Sell
13,670
-760
-5% -$15.8K 0.09% 218
2017
Q3 		$262K Buy
+14,430
New +$225K 0.09% 227

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Piermont Capital Management's CTMX Position: Q3 2018 in Review

Piermont Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 10,000 shares — an estimated $229K sold.

Piermont Capital Management first reported a position in CTMX in Q3 2017 and held it in 4 quarters. The position peaked at $336K in Q1 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Piermont Capital Management reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 10,000 CytomX Therapeutics shares in Q3 2018, an estimated $229K.
  • Piermont Capital Management first reported a position in CytomX Therapeutics in Q3 2017 and held it in 4 quarters.
  • Piermont Capital Management's CytomX Therapeutics position peaked at $336K in Q1 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.